Mixed Monoclonal Antibody Cocktail for Cancer Immunotherapy from Germany
This product is a blend of multiple monoclonal antibodies (e.g., pembrolizumab and nivolumab derivatives) designed for immunotherapy treatment of solid tumors. It falls under HTS 3002.14.00.90 as mixed immunological products not in measured doses or retail packaging, per chapter notes defining immunological products as peptides/proteins regulating immunological processes.
Duty Rate — Germany → United States
0%
Rate breakdown
9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Import Tips
• Obtain FDA biologics license application (BLA) approval prior to import; provide lot-specific certificates of analysis
• Declare as mixed immunological product; avoid retail packaging to stay in 3002.14, include biotech process details